Science

$Uyen Huynh-Do: Elranatamab for Relapsed/Refractory Multiple Myeloma with Severe Kidney Impairment$

Aug 16, 2025, 10:11

Uyen Huynh-Do: Elranatamab for Relapsed/Refractory Multiple Myeloma with Severe Kidney Impairment

Uyen Huynh-Do, Member of the Executive Board at University of Bern, shared a post on LinkedIn about recent paper she and colleagues co-authored:

“Relapsed/refractory multiple meloma (RRMM) patients with dialysis dependent renal impairment face limited therapeutic options due to exclusion from clinical trials, a lack of evidence-based guidelines, and inferior outcomes.

Here we present the case of a patient with ESRD (End stage Renal Disease) whom we treated with a bispecific antibody targeting B-cell maturation antigen BCMA (BCMA). The patient achieved a very good partial remission and the therapy was well-tolerated with manageable adverse events.

By providing real-world evidence for the use of bispecific antibodies in ESRD patients, this review emphasizes the potential for expanding therapeutic options to this vulnerable population.”

Title: Elranatamab for Relapsed/Refractory Multiple Myeloma With Severe Renal Impairment Requiring Hemodialysis

Authors: Michèle Hoffmann, Barbara Jeker, Uyen Huynh-Do, Yara Banz, Jeanne Godau, Elisabeth Weber, Ulrike Bacher, Thomas Pabst

Read The Full Article at Hematological Oncology.

$Uyen Huynh-Do: Elranatamab for Relapsed/Refractory Multiple Myeloma with Severe Kidney Impairment$

More Posts Featuring Multiple Myeloma.

Barbara Jeker cancer Elisabeth Weber Jeanne Godau Michèle Hoffmann multiple myeloma OncoDaily Oncology Relapsed/refractory multiple meloma renal disease Thomas Pabst Ulrike Bacher Uyen Huynh-Do Yara Banz

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Vinay Prasad Rejoins FDA Days After Exit

New Paper Alert: Safety and Outcomes of T-DXd Retreatment After Grade 1 ILD Recovery

FDA Accepts NDA for Vepdegestrant in ESR1-Mutant ER+/HER2- Advanced Breast Cancer

Hubert Caron Retires from Roche-Genentech